CEO Korenko Buys $99,600 of Vivos Stock at $0.498
RDGL sits 25% above its 52-week low of $0.04.
Summary
CEO Michael Korenko bought 200,000 shares of Vivos Inc. for $99,600 at $0.498 per share, raising his direct stake to 11.6 million shares.
Key Events · Ownership and Investor Activity · RDGL
-
CEO Open-Market Purchase
CEO Michael Korenko bought 200,000 shares at $0.498 per share for $99,600 on September 30, 2026.
-
Stake Increase
Post-transaction holdings rose to 11,635,090 shares, a direct ownership increase of roughly 1.7%.
-
Context: Going Concern
The purchase follows the August 12, 2026 10-Q that disclosed a going-concern warning and material weakness in internal controls.
-
FDA IDE Approval Backdrop
The company received FDA IDE approval for RadioGel in July 2026, providing a potential path to human clinical trials.
Analysis · RDGL · Industrial Applications And Services
CEO Michael Korenko bought 200,000 shares on the open market for $99,600 at $0.498 per share. This is a real-money purchase, not an option exercise or grant, and it comes just weeks after the company disclosed a going-concern warning and material weakness in its Q2 10-Q. The purchase represents roughly 0.4% of the company's market cap and increases Korenko's direct holdings to 11.6 million shares. For a nano-cap company under financial stress, a CEO putting nearly $100,000 of his own cash into the stock is a meaningful vote of confidence in the RadioGel and IsoPet pipeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RDGL was trading at $0.05 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $24.6M. The 52-week trading range was $0.04 to $0.12. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.